Neuroendocrine signature of ME/CFS: Meta-analytic evidence for bioactive cortisol deficit and exaggerated feedback sensitivity.

Mol PsychiatryApr 23, 2026 (epub)
Clinical ResearchEndocrinologyPsychiatryOpen access

Tae-Wook Woo, Yu-Jin Choi, Jun-Yeol Kim et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined the neuroendocrine profile of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) by analyzing 46 studies with 1388 patients. It found significantly lower salivary cortisol levels at awakening and throughout the day, indicating a bioactive cortisol deficit and heightened feedback sensitivity in the HPA axis, suggesting a hyporeactive endocrine state in ME/CFS.

Key findings

  • Lower salivary cortisol levels at awakening and in the morning were observed in ME/CFS patients.
  • 24-hour urinary cortisol and hair cortisol levels were also reduced in this population.
  • Patients showed impaired cortisol release in response to ACTH stimulation during pharmacological challenges.
  • Exaggerated suppression of cortisol was noted following glucocorticoid administration.

Why it matters

Understanding the neuroendocrine dysregulation in ME/CFS can help clinicians recognize the underlying mechanisms contributing to symptoms like fatigue and cognitive impairment, potentially guiding more effective management strategies.

Source

PubMed · PMID 42026257Free full text on PubMed Central

Published in Mol Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.